此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

The vBlocT2D Study

2019年4月25日 更新者:Kaiser Permanente

vBloc Therapy for Obese Subjects With Type 2 Diabetes- A Randomized Controlled Clinical Trial

Overall aim: To demonstrate that weight loss through vBloc Therapy in combination with usual care will achieve better glycemic control for patients with obesity and type 2 diabetes than usual care alone.

Duration: Participants will be asked to participate in a 12 month study that involves a baseline visit and research follow-up visits at 3, 6, 9, and 12 months.

Sample Size: 60 participants will be enrolled in the study. Of these, 30 will be randomized to vBloc therapy and 30 will be randomized to usual care.

研究概览

地位

撤销

详细说明

The vBlocT2D study is a two arm, randomized, controlled, unblinded clinical trial in which 60 adult patients with T2D with moderate to extreme obesity (BMI 35-45 kg/m2) and suboptimal glycemic control (glycated haemoglobin (HbA1c) 7-10%) without significant diabetic complications, will be randomized to usual care alone (n=30) or vBloc therapy plus usual care (n=30) to assess the superiority of vBloc therapy plus usual care than standard usual care alone in improving diabetic control. The vBloc therapy will be delivered through an electrical and reversible vagal blocking device (the Maestro Rechargeable System) implanted using laparoscopic surgery. The device was approved by the FDA in 2015 for weight loss in adults with BMI 40-45 kg/m2, or BMI 35-39.9 kg/m2 with one or more obesity-related co-morbid conditions. The study will recruit patients over a 12-month period and follow each individual for 12-months post intervention. The primary outcome is change in HbA1c at 12-months post randomization. The secondary outcomes are changes in weight, waist and hip circumferences, blood pressure, lipids, insulin sensitivity and β-cell health measured through oral glucose tolerance testing, dietary intake, eating behaviors, physical activity, quality of life and potential circulating biomarkers. Medication use, clinical labs and adverse events will be compared as well.

研究类型

介入性

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • California
      • Harbor City、California、美国、90710
        • Kaiser Permanente South Bay Medical Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Type 2 diabetes with HbA1c level 7-10% inclusive, AND known duration of disease ≤10 years, AND
  2. Male or female (females of child-birth potential not pregnant at implant or for duration of study), AND
  3. Age 18 years or older, AND
  4. Body mass index (BMI) 35-45 kg/m2 inclusive, AND
  5. Attempt and failed diet, exercise and behavioral modification program within past five years,

Exclusion Criteria:

  1. Use of GLP-1 receptor agonists for diabetes currently or within past 6 months
  2. Contraindications to vBloc (permanently implanted, electrical-powered medical device or gastrointestinal device or prosthesis (e.g. pacemakers, implanted defibrillators, neurostimulators))
  3. Patients for whom magnetic resonance imaging (MRI), shortwave, microwave, or therapeutic ultrasound diathermy is planned (Note: Diathermy is any treatment that uses high-frequency electromagnetic radiation, electric currents, or ultrasonic waves to produce heat in body tissues. Patients absolutely CANNOT be treated with any type of shortwave, microwave, or therapeutic ultrasound diathermy device whether or not it is used to produce heat. These treatments should not be applied anywhere on the body)
  4. Underlying disease(s) likely to (a) limit life span to less than study duration and/or (b) increase risk of intervention outside of the study and/or (c) limit ability to participate in outcomes assessment and/or (d) limit participation
  5. Previous bariatric or upper GI surgery
  6. Excessive alcohol intake
  7. Current smokers or smoking cessation in prior 3 months
  8. An underlying disease known to have important effects on glucose metabolism
  9. Active infections
  10. Anemia (Hemoglobin <11g/dl in women, <12 g/dl in men) or known coagulopathy
  11. Chronic kidney disease manifest as serum creatinine >2.0 mg/dl
  12. Diabetic retinopathy requiring photocoagulation therapy
  13. Symptomatic diabetic gastroparesis
  14. Cardiovascular disease, including uncontrolled hypertension and symptomatic congestive heart failure
  15. Cirrhosis of the liver, portal hypertension, or esophageal varices
  16. Symptomatic esophageal reflux
  17. Conditions or behaviors likely to affect the conduct of the vBloc Study

    1. Unable or unwilling to give informed consent
    2. Unable to adequately communicate with clinic staff
    3. Current or anticipated participation in another intervention research project that would interfere with any of the interventions/outcomes in vBloc study
    4. Likely to move away from participating clinic in next 2 years
    5. Current (or anticipated) pregnancy and lactation.
    6. Major psychiatric disorder that, in the opinion of investigators, would impede participation in the study
    7. Weight loss >7% in past two months for any reason except postpartum weight loss.
  18. Additional conditions may serve as criteria for exclusion at the discretion of the study investigators.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:vBloc Therapy + Usual Care for Type 2 Diabetes
The vBloc device will be placed using a laparoscopic procedure. The participants will be followed according to standard clinical practice and vBloc therapy protocol under the supervision of study surgeons. . Pre-operative testing will be conducted per surgeon's evaluation. Participants will receive weight management education according to the vBloc Therapy protocol.
无干预:Usual Care for Type 2 Diabetes

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Mean reduction in HbA1c
大体时间:at 12 months after baseline
at 12 months after baseline

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Anny Xiang, PhD、Kaiser Permanente

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2018年2月23日

初级完成 (实际的)

2018年11月30日

研究完成 (实际的)

2018年11月30日

研究注册日期

首次提交

2017年11月22日

首先提交符合 QC 标准的

2017年11月22日

首次发布 (实际的)

2017年11月28日

研究记录更新

最后更新发布 (实际的)

2019年4月29日

上次提交的符合 QC 标准的更新

2019年4月25日

最后验证

2019年4月1日

更多信息

与本研究相关的术语

其他研究编号

  • KPSC IRB 11343 (其他标识符:Kaiser Permanente Southern California IRB)

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

是的

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅